Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with a mutation in a protein.

A compound: ##STR00001##
wherein X.sup.1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y.sup.1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X.sup.2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH.sub.2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO.sub.2—NH—, and Y.sup.2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group, a piperazinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group, or —CR.sup.1R.sup.2R.sup.3 or alternatively X.sup.2—Y.sup.2 represents —CONR.sub.cR.sub.d, wherein R.sub.c and R.sub.d form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C.sub.1-C.sub.4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.

A compound: ##STR00001##
wherein X.sup.1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y.sup.1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X.sup.2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH.sub.2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO.sub.2—NH—, and Y.sup.2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group, a piperazinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group, or —CR.sup.1R.sup.2R.sup.3 or alternatively X.sup.2—Y.sup.2 represents —CONR.sub.cR.sub.d, wherein R.sub.c and R.sub.d form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C.sub.1-C.sub.4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.

Described herein are a method of preparing a vegetable oil, comprising pressing a non-fruit tissue of a date palm offshoot, as well as a vegetable oil and a polysaccharide-containing fraction obtained by such a method. Further described herein is an oil comprising esters of fatty acids, wherein at least 10 weight percent of the fatty acids are linolelaidic acid, as well as compositions comprising a variety of ingredients, such as saccharides and amino acids, as characterized herein, and a method of isolating dihydrouracil from an oil and/or composition described herein. Further described is a method of preparing a vegetable oil, comprising pressing date kernel tissue.

Described herein are a method of preparing a vegetable oil, comprising pressing a non-fruit tissue of a date palm offshoot, as well as a vegetable oil and a polysaccharide-containing fraction obtained by such a method. Further described herein is an oil comprising esters of fatty acids, wherein at least 10 weight percent of the fatty acids are linolelaidic acid, as well as compositions comprising a variety of ingredients, such as saccharides and amino acids, as characterized herein, and a method of isolating dihydrouracil from an oil and/or composition described herein. Further described is a method of preparing a vegetable oil, comprising pressing date kernel tissue.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.

The present invention relates to 4-methyldihydropyrimidinone compounds, or pharmaceutically acceptable salts thereof, having RORγ antagonist activity, pharmaceutical compositions comprising the same, and pharmaceutical use thereof. A compound of Formula (1) or (2) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and pharmaceutical use thereof are provided.

##STR00001##

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.